Effects of Coenzyme Q10 in PSP and CBD

Sponsor

Lahey Clinic (Other)

Overall Status

Completed

CT.gov ID

NCT00532571

Collaborator

(none)

Location

Duration (Months)

Study Details

Study Description

Brief Summary

To compare the efficacy, safety and tolerability of Coenzyme Q 10 versus placebo in patients with atypical parkinsonian syndromes corticobasal degeneration (CBD) and progressive supranuclear palsy (PSP) ).

Condition or Disease	Intervention/Treatment	Phase
Progressive Supranuclear Palsy Neurological Disorders	Drug: CoQ10	Phase 2/Phase 3

Study Design

Study Type:

Interventional

Allocation:

Randomized

Intervention Model:

Crossover Assignment

Masking:

Double

Primary Purpose:

Treatment

Official Title:

Effects of Coenzyme Q10 in PSP and CBD, A Randomized, Placebo-Controlled, Double Blind Cross Over Pilot Study

Study Start Date :

Jan 1, 2004

Study Completion Date :

Sep 1, 2005

Outcome Measures

Primary Outcome Measures

Eligibility Criteria

Criteria

Ages Eligible for Study:

40 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Patients fulfilling the diagnostic criteria of PSP and CBD (above) and who were diagnosed within the past 5 years
Age > 40
Subjects receiving anticholinergics, amantadine, dopamine agonists, carbidopa/levodopa, eldepryl, or comtan must be on a stable dose for at least 30 days prior to baseline visit.
Patients agreeable to participate in the study.

Exclusion Criteria:

Prior or concurrent therapy with anticholinergics, amantadine,a dopamine agonist,carbidopa/levodopa or comtan within 30 days of the baseline visit.
Parkinsons disease or any other atypical parkinsonism; Parkinsonism due to drugs.
History of pallidotomy, thalamotomy, deep brain stimulation or fetal tissue transplant.
Previous use of coenzyme Q10 within 60 days of the baseline visit.